Covaxin Efficacy Data
- All
- News
- Videos
-
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.
-
Covaxin Maker Says It's 81% Effective. What Next? A 7-Point Guide
Today, Bharat Biotech, the company that makes Covaxin, said that new data shows it is 81 per cent effective in protecting against COVID-19. This is interim analysis of Phase 3 of its trial. What does this data mean?
-
Covaxin 81% Effective, Works Against UK Variant, Claims Bharat Biotech
Covaxin is 81 per cent effective in preventing Covid and can work against the UK variant of the virus, Bharat Biotech said Wednesday as it revealed a "first interim analysis" of Phase III trial results for a vaccine cleared in January amid concerns over safety and efficacy.
-
"Don't Accuse Us Of Inexperience, We Are Global Company": Bharat Biotech
The chairman of Bharat Biotech - whose coronavirus vaccine Covaxin was yesterday given "restricted use in emergency situation in public interest" - hit out today at critics querying the lack of Phase III trial data and others questioning the drug's efficacy
-
"Disgraceful": Health Minister To Shashi Tharoor, Others On Vaccine Tweet
Health Minister Harsh Vardhan has criticised Congress and other opposition leaders over their comments on Bharat Biotech's Covaxin, which was cleared for emergency use in the country along with the Oxford-AstraZeneca vaccine manufactured by the Serum Institute of India.
-
No Efficacy Data For One Of Two Covid Vaccines Cleared By Government
The Indian Council for Medical Research (ICMR) confirmed today that it had not received Phase 3 efficacy or effectiveness data of one of the Covid vaccines that the government's drug regulator has cleared for emergency use.
-
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.
-
Covaxin Maker Says It's 81% Effective. What Next? A 7-Point Guide
Today, Bharat Biotech, the company that makes Covaxin, said that new data shows it is 81 per cent effective in protecting against COVID-19. This is interim analysis of Phase 3 of its trial. What does this data mean?
-
Covaxin 81% Effective, Works Against UK Variant, Claims Bharat Biotech
Covaxin is 81 per cent effective in preventing Covid and can work against the UK variant of the virus, Bharat Biotech said Wednesday as it revealed a "first interim analysis" of Phase III trial results for a vaccine cleared in January amid concerns over safety and efficacy.
-
"Don't Accuse Us Of Inexperience, We Are Global Company": Bharat Biotech
The chairman of Bharat Biotech - whose coronavirus vaccine Covaxin was yesterday given "restricted use in emergency situation in public interest" - hit out today at critics querying the lack of Phase III trial data and others questioning the drug's efficacy
-
"Disgraceful": Health Minister To Shashi Tharoor, Others On Vaccine Tweet
Health Minister Harsh Vardhan has criticised Congress and other opposition leaders over their comments on Bharat Biotech's Covaxin, which was cleared for emergency use in the country along with the Oxford-AstraZeneca vaccine manufactured by the Serum Institute of India.
-
No Efficacy Data For One Of Two Covid Vaccines Cleared By Government
The Indian Council for Medical Research (ICMR) confirmed today that it had not received Phase 3 efficacy or effectiveness data of one of the Covid vaccines that the government's drug regulator has cleared for emergency use.
